These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 10889150)

  • 1. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.
    Tibble JA; Sigthorsson G; Bridger S; Fagerhol MK; Bjarnason I
    Gastroenterology; 2000 Jul; 119(1):15-22. PubMed ID: 10889150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
    Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
    Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.
    Amati L; Passeri ME; Selicato F; Mastronardi ML; Penna A; Jirillo E; Covelli V
    Immunopharmacol Immunotoxicol; 2006; 28(4):665-81. PubMed ID: 17190742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can calprotectin predict relapse risk in inflammatory bowel disease?
    D'Incà R; Dal Pont E; Di Leo V; Benazzato L; Martinato M; Lamboglia F; Oliva L; Sturniolo GC
    Am J Gastroenterol; 2008 Aug; 103(8):2007-14. PubMed ID: 18802997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
    Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
    Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12.
    Däbritz J; Langhorst J; Lügering A; Heidemann J; Mohr M; Wittkowski H; Krummenerl T; Foell D
    Inflamm Bowel Dis; 2013 May; 19(6):1130-8. PubMed ID: 23377171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
    Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
    Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is moderate red wine consumption safe in inactive inflammatory bowel disease?
    Swanson GR; Tieu V; Shaikh M; Forsyth C; Keshavarzian A
    Digestion; 2011; 84(3):238-44. PubMed ID: 21876358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
    Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.